Drug Profile
DSP 3025
Alternative Names: AZD-3025; AZD-8848; DSP-3025Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer AstraZeneca; Sumitomo Pharma
- Class Antiasthmatics; Small molecules
- Mechanism of Action Immunomodulators; Toll-like receptor 7 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic asthma; Seasonal allergic rhinitis